 | This article needs additional citations for verification .(June 2009) |
The Rogosin Institute is an independent, not-for-profit treatment and research center with facilities throughout New York City that treat patients with kidney disease, including dialysis and kidney transplantation; lipid disorders; and hypertension. It is affiliated with NewYork-Presbyterian Hospital, Weill Cornell Medical College and is a leader in research programs for cancer and diabetes.
The Rogosin Institute has been providing care to patients for fifty two years and pioneered in the treatment of kidney failure and kidney transplantation through hemodialysis.
In 1957, the Rogosin team performed the first hemodialysis in the New York metropolitan area as a treatment for kidney failure. In 1962, the unit became known as the Renal Laboratory and moved to the New York Hospital-Cornell Medical Center where it expanded to the Rogosin Renal Laboratories, named in honor of Israel Rogosin (1886-1971), an American textile industrialist and philanthropist who supported the New York Hospital-Cornell Medical Center. In 1963, The Rogosin Institute performed the first kidney transplant in the New York area.
With expansion into research and treatment of cardiovascular disease and cancer, The Rogosin Institute became an independent corporate entity in 1983. In 1988, many of The Rogosin Institute's facilities were brought together in The New York Hospital's Helmsley Medical Tower at 70th Street and York Avenue. The historical administrative records of the Institute are housed in the Medical Center Archives of NewYork-Presbyterian/Weill Cornell. [1]
The institute provides 80,000 dialyses each year[ citation needed ]. In addition to traditional hemodialysis, The Rogosin Institute offers patients a number of options, including peritoneal dialysis and home nocturnal hemodialysis. Dialysis centers are located in Manhattan, Brooklyn, and Queens.
The Rogosin Institute is a pioneer in the implementation of technologies that make kidney transplantation more accessible and successful, such as programs for highly sensitized transplant recipients, the use of steroid-free protocols, desensitizing programs for incompatible donors, and donor exchange programs. The institute has completed more than 3,000 successful transplants. [2]
The Rogosin Institute Comprehensive Lipid Control Center is a research and treatment center for adults and children with cholesterol and triglyceride disorders that provides a full range of diagnostic and individualized treatment plans. The institute pioneered clinical research of LDL apheresis [3] in the early 1980s, which led to the adoption of the procedure to treat patients with the genetic form of extremely high cholesterol.
Physicians at the institute treat hypertension in patients with hypertension alone and in those with both hypertension and kidney disease.
Investigators at the institute are involved in early clinical testing of possible treatments for cancer [4] and diabetes. The cancer research is based on the principle that all living cells have some built-in control of their growth and development. The research involves using encapsulated cancer cells that release substances that signal cancer cells to slow or stop their growth. Responses in tumors and improved quality of life for patients have been observed and additional studies are underway.[ when? ]
Diabetes research at The Rogosin Institute was stimulated by the fact that diabetes is the largest cause of end-stage kidney disease. Research began in 1987 on a process that replaces cells that produce insulin in the body (beta cells in the islets of the pancreas) in order to reverse insulin-dependent diabetes. The research involves a unique encapsulation of islet cells and early testing is underway.[ citation needed ][ when? ]
Scientists at the Rogosin Institute have developed non-invasive procedures, less expensive and less painful than renal biopsies, for diagnosing rejection of transplanted kidneys. [5]
Nephrology is a specialty of adult internal medicine and pediatric medicine that concerns the study of the kidneys, specifically normal kidney function and kidney disease, the preservation of kidney health, and the treatment of kidney disease, from diet and medication to renal replacement therapy. The word “renal” is an adjective meaning “relating to the kidneys”, and its roots are French or late Latin. Whereas according to some opinions, "renal" and "nephro" should be replaced with "kidney" in scientific writings such as "kidney medicine" or "kidney replacement therapy", other experts have advocated preserving the use of renal and nephro as appropriate including in "nephrology" and "renal replacement therapy", respectively.
Kidney dialysis is the process of removing excess water, solutes, and toxins from the blood in people whose kidneys can no longer perform these functions naturally. This is referred to as renal replacement therapy. The first successful dialysis was performed in 1943.
Kidney failure, also known as end-stage kidney disease, is a medical condition in which the kidneys can no longer adequately filter waste products from the blood, functioning at less than 15% of normal levels. Kidney failure is classified as either acute kidney failure, which develops rapidly and may resolve; and chronic kidney failure, which develops slowly and can often be irreversible. Symptoms may include leg swelling, feeling tired, vomiting, loss of appetite, and confusion. Complications of acute and chronic failure include uremia, high blood potassium, and volume overload. Complications of chronic failure also include heart disease, high blood pressure, and anemia.
Hemodialysis, also spelled haemodialysis, or simply dialysis, is a process of purifying the blood of a person whose kidneys are not working normally. This type of dialysis achieves the extracorporeal removal of waste products such as creatinine and urea and free water from the blood when the kidneys are in a state of kidney failure. Hemodialysis is one of three renal replacement therapies. An alternative method for extracorporeal separation of blood components such as plasma or cells is apheresis.
Kidney disease, or renal disease, technically referred to as nephropathy, is damage to or disease of a kidney. Nephritis is an inflammatory kidney disease and has several types according to the location of the inflammation. Inflammation can be diagnosed by blood tests. Nephrosis is non-inflammatory kidney disease. Nephritis and nephrosis can give rise to nephritic syndrome and nephrotic syndrome respectively. Kidney disease usually causes a loss of kidney function to some degree and can result in kidney failure, the complete loss of kidney function. Kidney failure is known as the end-stage of kidney disease, where dialysis or a kidney transplant is the only treatment option.
Chronic kidney disease (CKD) is a type of kidney disease in which there is gradual loss of kidney function over a period of months to years. Initially there are generally no symptoms; later, symptoms may include leg swelling, feeling tired, vomiting, loss of appetite, and confusion. Complications can relate to hormonal dysfunction of the kidneys and include high blood pressure, bone disease, and anemia. Additionally CKD patients have markedly increased cardiovascular complications with increased risks of death and hospitalization.
Peritoneal dialysis (PD) is a type of dialysis which uses the peritoneum in a person's abdomen as the membrane through which fluid and dissolved substances are exchanged with the blood. It is used to remove excess fluid, correct electrolyte problems, and remove toxins in those with kidney failure. Peritoneal dialysis has better outcomes than hemodialysis during the first couple of years. Other benefits include greater flexibility and better tolerability in those with significant heart disease.
Diabetic nephropathy, also known as diabetic kidney disease, is the chronic loss of kidney function occurring in those with diabetes mellitus. Diabetic nephropathy is the leading causes of chronic kidney disease (CKD) and end-stage renal disease (ESRD) globally. The triad of protein leaking into the urine, rising blood pressure with hypertension and then falling renal function is common to many forms of CKD. Protein loss in the urine due to damage of the glomeruli may become massive, and cause a low serum albumin with resulting generalized body swelling (edema) so called nephrotic syndrome. Likewise, the estimated glomerular filtration rate (eGFR) may progressively fall from a normal of over 90 ml/min/1.73m2 to less than 15, at which point the patient is said to have end-stage renal disease. It usually is slowly progressive over years.
Kidney transplant or renal transplant is the organ transplant of a kidney into a patient with end-stage kidney disease (ESRD). Kidney transplant is typically classified as deceased-donor or living-donor transplantation depending on the source of the donor organ. Living-donor kidney transplants are further characterized as genetically related (living-related) or non-related (living-unrelated) transplants, depending on whether a biological relationship exists between the donor and recipient.
Artificial kidney is often a synonym for hemodialysis, but may also, refer to renal replacement therapies that are in use and/or in development. This article deals with bioengineered kidneys/bioartificial kidneys that are grown from renal cell lines/renal tissue.
The Kolling Institute is located on the grounds of the Royal North Shore Hospital in St Leonards, Sydney Australia. The institute, founded in 1920, is the oldest medical research institute in New South Wales.
Northwest Kidney Centers is a regional, not-for-profit community-based provider of kidney dialysis, public health education, and research into the causes and treatments of chronic kidney disease. Established in Seattle in 1962, it was the world's first out-of-hospital dialysis provider. It offers dialysis throughout the greater Seattle area in 20 free-standing clinics, eight hospitals and its home dialysis program. It opened its first clinic in Everett in 2020, the organization's first in Snohomish county.
Robert Provenzano is an American nephrologist. He is also an Associate Clinical Professor of Medicine at Wayne State University School of Medicine.
T. Alp Ikizler is a nephrologist, currently holding the Catherine McLaughlin Hakim chair in Medicine at Vanderbilt University School of Medicine, where he does clinical work and heads a research lab. Born in Istanbul, Turkey, he received his M.D. from the Istanbul University Faculty of Medicine.
Nathan W. Levin is an American physician and founder of the Renal Research Institute, LLC., a research institute dedicated to improving the outcomes of patients with kidney disease, particularly those requiring dialysis. Levin is one of the most prominent and renowned figures in clinical nephrology as well as nephrology research. He has authored multiple book chapters and over 350 peer-reviewed publications, including articles in leading journals such as Nature, the New England Journal of Medicine, and The Lancet.
The Sindh Institute of Urology & Transplantation (SIUT) is a dialysis & kidney transplant centre located in Pakistan. SIUT was founded by Dr. Adibul Hasan Rizvi and it is Pakistan's largest kidney disease center, as well as Pakistan's largest public sector health organisation. It began as a department of urology at the government-run Civil Hospital in 1970 and became autonomous in 1991. Ten to twelve transplants are performed weekly, and in 2003, doctors at SIUT performed Pakistan's first liver transplant. In 2004, a child care unit was opened.
Kamyar Kalantar-Zadeh is an Iranian-American physician doing research in nephrology, kidney dialysis, nutrition, and epidemiology. He is best known as a specialist in kidney disease nutrition and chronic kidney disease and for his hypothesis about the longevity of individuals with chronic disease states, also known as reverse epidemiology including obesity paradox. According to this hypothesis, obesity or hypercholesterolemia may counterintuitively be protective and associated with greater survival in certain groups of people, such as elderly individuals, dialysis patients, or those with chronic disease states and wasting syndrome (cachexia), whereas normal to low body mass index or normal values of serum cholesterol may be detrimental and associated with worse mortality. Kalantar-Zadeh is also known for his expertise in kidney dialysis therapy, including incremental dialysis, as well as renal nutrition. He is the brother of Kourosh Kalantar-zadeh, who an Australian scientist involved in research in the fields of materials sciences, nanotechnology, and transducers.
Onconephrology is a specialty in nephrology that deals with the study of kidney diseases in cancer patients. A nephrologist who takes care of patients with cancer and kidney disease is called an onconephrologist. This branch of nephrology encompasses nephrotoxicity associated with existing and novel chemotherapeutics, kidney disease as it pertains to stem cell transplant, paraneoplastic kidney disorders, paraproteinemias, electrolyte disorders associated with cancer, and more as discussed below.
Sree Bhushan Raju M.D., D.M., Diplomate of National Board, is a nephrologist from Telangana, India. He is currently professor and head, Dept of Nephrology, Nizam's Institute of Medical Sciences Panjagutta, Hyderabad. Which is one of the largest teaching Department in India having eight DM seats. He is one of the principal investigators of CKD task force by Indian Council of Medical Research (ICMR) to evaluate the prevalence of CKD in adult urban population in India.
Jochen Reiser is a physician-scientist and a healthcare leader. He is the Ralph C Brown MD Professor and the Chairman of Medicine at Rush University Medical Center. Dr. Reiser's research has provided important mechanistic insights into the molecular pathogenesis of kidney diseases. Dr. Reiser discovered the role of suPAR as a global, circulating risk factor for chronic kidney disease (CKD) as well as for acute kidney injury (AKI). suPAR is investigated as potential causative agent contributing to many kidney diseases including focal segmental glomerulosclerosis (FSGS). These studies have broad clinical significance and lay the foundation for creation of novel diagnostics and pharmaco-therapeutics with potential benefit for a large patient population. His studies on suPAR molecule were featured in Science in 2018. Dr. Reiser has been an advocate of science and innovation for two decades and was named as an inventor on multiple patents. He is co-founder of Cambridge, MA-based Walden Biosciences, an ARCH Venture Partners joint-venture biopharmaceutical portfolio company dedicated to develop first-in-class therapeutics for kidney diseases.
{{cite web}}: CS1 maint: archived copy as title (link)Coordinates: 40°45′56″N73°57′16″W / 40.765487°N 73.954307°W
| General | |
|---|---|
| National libraries | |
